Research
Hormonal
No significant heterogeneity of treatment effects was found by age, race, ethnicity, baseline BMI, or baseline HbA1c.
GLP-1 receptor agonists may be effective regardless of age, race, ethnicity, BMI, or HbA1c levels.
StrongRefutesmedium confidence
We found no significant HTE by age, race, ethnicity, baseline BMI, or baseline HbA1c.
Why this rating
Based on meta-analysis of multiple RCTs.
Source
Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults
G. Caleb Alexander et al. · JAMA Internal Medicine · 2026
DOI 10.1001/jamainternmed.2025.8222
Meta-analysisCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →